Abstracts tagged "Disease Activity"

Abstract Number: 1809 • ACR Convergence 2021
Efficacy of Tofacitinib on Enthesitis in Patients with Active Psoriatic Arthritis
Philip Mease¹, Ana-Maria Orbai², Oliver FitzGerald³, Mohamed Bedaiwi⁴, Dona L Fleishaker⁵, Rajiv Mundayat⁶, Pamela Young⁷ and Philip S Helliwell⁸, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ⁴Division of Rheumatology, College of Medicine, King Saud University Medical City, Riyadh, Saudi Arabia, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Collegeville, PA, ⁸Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Enthesitis (inflammation where the tendon, ligament, or joint capsule insert into the bone) has been associated with higher disease activity and reduced quality of…
Abstract Number: 0272 • ACR Convergence 2021
RA Disease Activity Is an Independent Predictor of Left Ventricular Mass Changes in an RA Cohort Without Cardiovascular Disease
Elizabeth Park¹, Kazato Ito¹, Christopher Depender¹, Jon Giles¹ and Joan Bathon², ¹Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, ²Columbia University, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) patients have 50% increased risk of heart failure (HF) vs non-RA patients with a distinct phenotype, preserved ejection fraction on transthoracic…
Abstract Number: 0605 • ACR Convergence 2021
Impact of Area of Residence on Perceptions of Health and Disease Activity in Ethnic Minorities with Rheumatoid Arthritis in an Urban Setting
Mohamed Jalloh¹, Sharon Dowell², Richard Ogunti¹ and Gail Kerr³, ¹Howard University Internal Medicine Residency, Washington, DC, ²Howard University College of Medicine, Washington, DC, ³Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC
Background/Purpose: Health care disparities in hypertension and other chronic disease are well established. Ethnic minority residents of Washington DC, particularly Wards 7 and 8, have…
Abstract Number: 0818 • ACR Convergence 2021
Biologics Initiation in Moderate vs Severe Rheumatoid Arthritis Patients: Prospective Observational Study from a Canadian Registry
Nancy Guo¹, Xiuying Li², Mohammad Movahedi³, Angela Cesta⁴ and Claire Bombardier⁵, ¹Kingston General Hospital, Kingston, ON, Canada, ²OBRI at University Health Network, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Prior studies have shown that in the real-world setting, rheumatoid arthritis (RA) patients have lower disease activity than those studied in clinical trials. However,…
Abstract Number: 1045 • ACR Convergence 2021
Composition of Phospholipid Fatty Acids in Erythrocyte Membranes from Patients with Ankylosing Spondylitis
Junming Chen, Xuechan Huang, Qidang Huang, Zhixiang Huang, Yukai Huang, Yuqi Liu, Lixin Huang, Shanmiao Sun, Zhuyi ji and Tianwang Li, Guangdong Second Provincial General Hospital, Guangzhou, China (People's Republic)
Background/Purpose: To investigate the composition of phospholipid fatty acids in erythrocyte membranes from patients with ankylosing spondylitis (AS), and determine the correlations between the percentage…
Abstract Number: 1276 • ACR Convergence 2021
Predictors of Remission (on and off Treatment) and Lupus Low Disease Activity State (LLDAS) in Systemic Lupus Erythematosus (SLE): Data from a Multinational, Multicenter SLICC (Systemic Lupus International Collaborating Clinics) Cohort
Manuel Ugarte-Gil¹, Guillermo Ruiz-Irastorza², Dafna Gladman³, Murray Urowitz⁴, Ann Clarke⁵, John Hanly⁶, Caroline Gordon⁷, Sang-Cheol Bae⁸, Juanita Romero-Diaz⁹, Jorge Sanchez-Guerrero¹⁰, Sasha Bernatsky¹¹, Daniel Wallace¹², David Isenberg¹³, Anisur Rahman¹⁴, Joan Merrill¹⁵, Paul R Fortin¹⁶, Ian N. Bruce¹⁷, Michelle Petri¹⁸, Ellen Ginzler¹⁹, Mary Anne Dooley²⁰, Rosalind Ramsey-Goldman²¹, Susan Manzi²², Andreas Jnsen²³, Ronald F van Vollenhoven²⁴, Cynthia Aranow²⁵, Meggan Mackay²⁵, S Sam Lim²⁶, Murat Inanc²⁷, Kenneth Kalunian²⁸, Soren Jacobsen²⁹, Christine Peschken³⁰, Diane Kamen³¹, Anca Askanase³², Bernardo A. Pons-Estel³³ and Graciela Alarcn³⁴, ¹Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ²Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶Dalhousie University, Halifax, NS, Canada, ⁷Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁸Hanyang University Medical Center, Seoul, Republic of Korea, ⁹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, ¹⁰Instituto Nacional de Ciencias Médicas y Nutrición, Inmunología y Reumatología, Mexico City, Mexico, ¹¹McGill University, Montréal, QC, Canada, ¹²Cedars-Sinai, Los Angeles, CA, ¹³Centre for Rheumatology, University College London, London, United Kingdom, ¹⁴University College London, London, United Kingdom, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹⁷University of Manchester, Manchester, United Kingdom, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹SUNY Downstate Health Sciences University, Brooklyn, NY, ²⁰Raleigh Neurology Associates, Chapel Hill, NC, ²¹Northwestern University, Chicago, IL, ²²Allegheny Health Network, Wexford, PA, ²³Lund University, Lund, Sweden, ²⁴Amsterdam University Medical Centers, Department of Rheumatology and Clinical Immunology, Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²⁵Feinstein Institutes for Medical Research, Manhasset, NY, ²⁶Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ²⁷Istanbul University Faculty of Medicine, Istanbul, Turkey, ²⁸UC San Diego, La Jolla, CA, ²⁹Rigshospitalet, Copenhagen, Denmark, ³⁰University of Manitoba, Winnipeg, MB, Canada, ³¹Medical University of South Carolina, Charleston, SC, ³²Columbia University Medical Center, New York, NY, ³³Grupo Oroo - Centro Regional de Enfermedades Autoinmunes y Reumticas (GO-CREAR), Rosario, Argentina, ³⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Remission and LLDAS have been proposed as the goals for the treatment of SLE patients. However, the predictors of each state remain unknown. The…
Abstract Number: 1539 • ACR Convergence 2021
High Disease Activity, as Assessed by RAPID3, Increases Risk of Hospitalization and Predicts Lower Chance of Recovery from COVID-19 in a Cohort of Tertiary Care Rheumatology Patients
Matas Orentas¹, Sonali Khandelwal², Michael Grant², Yanyu Zhang¹, Najia Shakoor² and Sobia Hassan¹, ¹RUMC, Chicago, IL, ²Rush University, Chicago, IL
Background/Purpose: There is a need to understand which patients with rheumatologic diseases may be at highest risk for poor COVID-19 related outcomes so that both…
Abstract Number: 1817 • ACR Convergence 2021
Comparison of Composite Indices for Disease Activity in Patients with Psoriatic Arthritis Treated with Upadacitinib: A Post-Hoc Analysis from SELECT-PsA 1
Josef Smolen¹, Ennio Lubrano², Mitsumasa Kishimoto³, Andra R Bălănescu⁴, Vibeke Strand⁵, Tianming Gao⁶, Nancy Vranich⁶, Ralph Lippe⁷ and William Tillett⁸, ¹Medical University of Vienna, Vienna, Austria, ²Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy, ³Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁴“Carol Davila” University of Medicine and Pharmacy, Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ⁵Stanford University School of Medicine, Portola Valley, CA, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Deutschland GmbH & Co. KG, Berlin, Germany, ⁸Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: Achieving low disease activity (LDA) or remission is a main treatment target in PsA. Composite indices used to assess disease activity include Disease Activity…
Abstract Number: 0275 • ACR Convergence 2021
Impact of Disease Activity on Left Ventricular Diastolic Dysfunction in Rheumatoid Arthritis Patients
Natalia Guajardo-Jauregui, Dionicio Galarza-Delgado, Iris Colunga-Pedraza, Jose Azpiri-Lopez, Alejandra Rodriguez-Romero, Alejandro Meza-Garza, Julieta Loya-Acosta, Jesus Cardenas-de La Garza, Salvador Lugo-Perez, Catalina Andrade-Vazquez and Alan De Leon-Yañez, Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico
Background/Purpose: Cardiovascular disease (CVD) is the main cause of mortality in patients with rheumatoid arthritis (RA) reflected by a higher prevalence of cardiovascular risk factors…
Abstract Number: 0631 • ACR Convergence 2021
Provider Assessment of Telehealth Utility During COVID-19
Catherine Howe¹, Isaac Smith¹, Robert Overton², Ricardo Henao², Nicoleta Economou-Zavlanos², Jayanth Doss³, Megan Clowse⁴ and David Leverenz³, ¹Duke University Hospital, Durham, NC, ²Duke Clinical Research Institute, Durham, NC, ³Duke University, Durham, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: The COVID-19 pandemic forced the provision of telehealth care to rheumatology patients with a broader range of diagnoses and disease activity than previously studied.…
Abstract Number: 0836 • ACR Convergence 2021
Flare After Switching from Intravenous Tocilizumab to Subcutaneous Formulation in Patients with Rheumatoid Arthritis
Soo Min Ahn¹, Ji Seon Oh², Hyun Mi Heo³, Seokchan Hong³, Chang-Keun Lee³, Bin Yoo¹ and Yong-Gil Kim³, ¹ASAN MEDICAL CENTER, Seoul, South Korea, ²Asan Medical Center, Ulsan, Republic of Korea, ³Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Interleukin-6 (IL-6) plays a key role in inflammatory and immune responses. Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody of the IL-6 receptor which…
Abstract Number: 1167 • ACR Convergence 2021
Rheumatoid Arthritis Patients’ Treatment Goals Relate to Disease Activity and Rheumatology Experiences
Kelly O'Neill¹, Pamela Sinicrope², Kathryne Marks³, Elena Myasoedova², Cynthia Crowson⁴ and John Davis², ¹Rheumatoid Patient Foundation, Lutz, FL, ²Mayo Clinic, Rochester, MN, ³Rheumatoid Patient Foundation, Boston, MA, ⁴Mayo Clinic, Eyota, MN
Background/Purpose: Shared decision making and treat to target are recognized guidelines to treat Rheumatoid Arthritis (RA). We previously reported associations of shared treatment goal discussions…
Abstract Number: 1282 • ACR Convergence 2021
Classification of Disease Activity and Damage in Cutaneous Lupus
Laila Abbas, Karabi Nandy and Benjamin Chong, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The Cutaneous Lupus Disease Area and Severity Index (CLASI) can quantify disease activity and damage in Cutaneous Lupus Erythematosus (CLE). Classification of CLASI scores…
Abstract Number: 1618 • ACR Convergence 2021
Disease Flares in CANDLE/PRAAS with Dose Reductions of Baricitinib
Kader Cetin Gedik¹, Grace Materne², Ana Ortega-Villa³, Gina Montealegre Sanchez⁴, Adam Reinhardt⁵, Paul Brogan⁶, Yackov Berkun⁷, Sara Murias⁸, Maria Robles⁹, Susanne Schalm¹⁰, Adriana Almeida de Jesus¹¹ and Raphaela Goldbach-Mansky¹², ¹Translational Autoinflammatory Diseases Section (TADS)/NIAID/NIH, Bethesda, MD, ²Translational Autoinflammatory Diseases Section, NIAID/NIH, Bethesda, TN, ³Biostatistics Research Branch, Division of Clinical Research, NIAID/NIH, Bethesda, ⁴NIAID/NIH, Bethesda, MD, ⁵Boys Town National Research Hospital, Omaha, NE, ⁶UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁷Hadassah Hebrew University Medical Center, Jerusalem, Israel, ⁸Hospital Infantil La Paz, Madrid, Spain, ⁹Eskenazi Health Center, IndianaPolis, IN, ¹⁰Rheumatologie im Zentrum, Munich, Germany, ¹¹TADS/NIAID/NIH, Silver Spring, MD, ¹²NIH/NIAID, Potomac, MD
Background/Purpose: Patients with chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures /proteasome-associated autoinflammatory syndrome (CANDLE/PRAAS) respond to treatment with baricitinib but require higher exposure…
Abstract Number: 1826 • ACR Convergence 2021
Reduced Burden on Paid and Household Work Productivity with Stringent Thresholds of Disease Control: Further Results from Long-Term Certolizumab Pegol Treatment in Patients with Psoriatic Arthritis
William Tillett¹, Laura Coates², Sandeep Kiri³, Vanessa Taieb³ and Philip Mease⁴, ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³UCB Pharma, Slough, United Kingdom, ⁴Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: Psoriatic arthritis (PsA) is associated with a reduction in workplace productivity,1 which may extend into household productivity.2 Certolizumab pegol (CZP) is a tumor necrosis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].